Assuring patient-centred care: engaging patients with rheumatoid arthritis in disease monitoring and pharmacovigilance
Journal Title: Generics and Biosimilars Initiative Journal - Year 2014, Vol 3, Issue 1
Abstract
With the advent of complex therapies in the form of biologicals, emerging biosimilars and non-biological complex drugs, monitoring for treatment related benefit and the potential for adverse effects is as critical as monitoring for signs and symptoms of rheumatoid arthritis disease progression. With a focus on strengthening patient and provider education and engagement, patients can be successfully engaged in the long-term monitoring of their disease and play a vital role in the determination of adequate treatment response or treatment failure.
Authors and Affiliations
Janet S Wyatt
Keywords
Related Articles
- EP ID EP354177
- DOI 10.5639/gabij.2014.0301.008
- Views 148
- Downloads 0
WHO leadership in public safety on biosimilars to be commended
As a practicing endocrinologist and Chairman of the Alliance for Safe Biologic Medicines, I am writing to commend the World Health Organization for its attention to and upcoming action on the important issue of non-propr...
Tyrosine kinase inhibitors becoming generic drugs – risks and chances from a regulatory perspective
Aim: To provide a systematic overview on: i) safety profiles; ii) pharmacokinetic parameters; and iii) regulatory framework of anti-cancer tyrosine kinase inhibitors (TKI). Methodology: Recherché of pharmakokinetic (PK)-...
Analysis of European policy towards generic medicines
In this paper, we provide an overview of a PhD project we undertook on European policy on generic medicines. In the course of our research, we identified various causes for delayed market access of generic medicines and...
A review of generic medicine pricing in Europe
Introduction: Switching from originator products to generic equivalents is a key method used by governments to reduce costs and keep their healthcare systems sustainable. The aim of this article is to review generic medi...
Defining and characterizing non-biological complex drugs (NBCDs) – Is size enough? The case for liposomal doxorubicin generics (‘liposomal nanosimilars’) for injection
‘Non-binding recommendations’ from regulatory bodies are in place for evaluation and production of generic liposomal doxorubicin injection. However, how these nano-sized generics (‘nanosimilars’) should be characterized...